The Food and Drug Administration (FDA) has approved Journavx™ (suzetrigine) for the treatment of moderate to severe acute pain in adults.

The decline in cancer incidence among men and increase among women has narrowed the male‐to-female cancer incidence rate ratio from a peak of 1.6 in 1992 to 1.1 in 2021. In people aged 50-64 years, ...

The researchers found that imlunestrant prolonged progression-free survival (PFS) when compared to standard care in patients with ESR1 mutations, but there was no PFS benefit observed in the overall ...